Mechanisms of polarization of monocytes by DAMPs/PAMPs and C1q
DAMPs/PAMPs 和 C1q 的单核细胞极化机制
基本信息
- 批准号:10163790
- 负责人:
- 金额:$ 41.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAnti-Inflammatory AgentsAtherosclerosisAutoimmune DiseasesBindingCellsCollagenComplementComplement 1qCytoskeletonDiseaseEndotheliumExposure toFlareGoalsHMGB1 geneHomeostasisHumanImmuneImmune systemImmunoglobulinsInflammationInflammatoryInterferonsIntraperitoneal InjectionsInvestigationLeadLeukocytesLeukotriene ProductionLeukotrienesMaintenanceMediatingMediator of activation proteinMicroRNAsModelingMolecularMusMyelogenousMyeloid CellsObesityOutcomePTPN6 genePathologyPathway interactionsPatternPattern recognition receptorPeritonitisPhosphorylationProcessProductionResearchResolutionSignal PathwaySignal TransductionSystemic Lupus ErythematosusTailTestingTherapeuticToll-like receptorsactivation productbasecell typechronic inflammatory diseasecomplement 1q receptorcytokineimmunoregulationimprovedinhibitor/antagonistinsightlipid mediatormacrophagemonocytenovelpathogenpreventprogramsreceptorreceptor for advanced glycation endproductsrepairedresponse
项目摘要
PROJECT SUMMARY/ABSTRACT
Systemic Lupus Erythematosus (SLE) is a disease characterized by high levels of HMGB1 and low levels of
C1q. The damage-associated molecular pattern (DAMP) HMGB1 and its receptor RAGE trigger production of
interferon and pro-inflammatory cytokines and induce an M1-like polarization. Complement component C1q
exerts a suppressive effect on monocyte activation. Exposure of monocytes to HMGB1 plus C1q leads to an
M2-like polarization. This polarization of monocytes to an anti-inflammatory M2-like program is not seen when
monocytes are exposed to C1q alone. As both HMGB1 and C1q are evolutionarily old molecules and are
highly conserved, we believe this is likely an important paradigm for monocyte differentiation and resolution of
inflammation. Imbalances in M1/ M2 polarization are maladaptive; in the extreme, as mentioned above, they
lead to SLE and in less extreme forms to “non-resolving inflammation”. We propose further studies in human
monocytes to explore the molecular mechanism of macrophage polarization by HMGB1 and HMGB1 plus C1q.
We hypothesize that HMGB1 signaling through RAGE and HMGB1 plus C1q co-ligating RAGE and LAIR-1
have functions relevant to the maintenance of homeostasis both in humans and mice through regulating
cytokine expression, lipid mediators and microRNAs. We will first test the contribution of Vav and SHP-1 to
macrophage mediated inflammation and resolution (Aim 1). Next, we will determine whether HMGB1 and
HMGB1 plus C1q differentially regulate production of leukotrienes and specialized pro-resolving mediators
(SPMs) (Aim 2). Finally, we will delineate up-or down-regulated microRNAs in HMGB1 and HMGB1 plus C1q
exposed cells. We will define their tolerance mechanisms (Aim 3). These lines of investigation will 1) offer
novel insights into the molecular mechanism of M2-like macrophage polarization, 2) contribute new models to
the study of immune regulation, and 3) improve our understanding, and therapeutic options for SLE, and
conditions with poor resolution of inflammation.
项目总结/摘要
系统性红斑狼疮(SLE)是一种以高水平HMGB 1和低水平HMGB 2为特征的疾病。
C1q。损伤相关分子模式(DAMP)HMGB 1及其受体介导的HMGB 1的产生,
干扰素和促炎细胞因子并诱导M1样极化。补体成分C1 q
对单核细胞活化发挥抑制作用。单核细胞暴露于HMGB 1 + C1 q导致
M2类极化。这种单核细胞向抗炎性M2样程序的极化在以下情况下未观察到:
单核细胞单独暴露于C1 q。由于HMGB 1和C1 q都是进化上古老的分子,
高度保守,我们相信这可能是单核细胞分化和解决
炎症M1/ M2极化的不平衡是不适应的;在极端情况下,如上所述,它们
导致SLE,并在不太极端形式中导致“非消退性炎症”。我们建议进一步研究人类
探讨HMGB 1和HMGB 1 + C1 q对巨噬细胞极化的分子机制。
我们假设HMGB 1信号通过HMGB 1和HMGB 1加上C1 q共同连接HMGB 1和LAIR-1,
具有通过调节维持人和小鼠体内稳态的相关功能
细胞因子表达、脂质介质和microRNA。我们将首先测试Vav和SHP-1对
巨噬细胞介导的炎症和消退(目的1)。接下来,我们将确定HMGB 1和
HMGB 1加C1 q差异调节白三烯和专门的促消退介质的产生
(目标2)。最后,我们将描述HMGB 1和HMGB 1 + C1 q中上调或下调的microRNA
暴露的细胞我们将定义他们的耐受机制(目标3)。这些调查路线将提供
对M2样巨噬细胞极化的分子机制的新见解,2)为
免疫调节的研究,3)提高我们对SLE的理解和治疗选择,
炎症消退差的病症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Myoungsun Son其他文献
Myoungsun Son的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Myoungsun Son', 18)}}的其他基金
Mechanisms of polarization of monocytes by DAMPs/PAMPs and C1q
DAMPs/PAMPs 和 C1q 的单核细胞极化机制
- 批准号:
10408116 - 财政年份:2018
- 资助金额:
$ 41.19万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 41.19万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 41.19万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 41.19万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 41.19万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 41.19万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 41.19万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 41.19万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 41.19万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 41.19万 - 项目类别:














{{item.name}}会员




